Does Retatrutide Cause Diarrhea?

Summary: Retatrutide caused diarrhea in roughly 21% of participants at the 12 mg dose in the Phase 2 obesity trial, and the rate is dose dependent because glucagon receptor agonism adds a GI signal that single GLP-1 drugs do not have.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: yes. In the Phase 2 obesity trial published in the New England Journal of Medicine in 2023, diarrhea hit about 21% of participants on the 12 mg dose of retatrutide, compared with 9% on placebo ^[1]. The rate scales with dose. The lower the dose, the closer your diarrhea risk gets to the placebo floor. At full therapeutic doses, roughly one in five users will report at least one episode, and most of those episodes cluster in the first weeks after a dose increase.

That is the headline. Below is what the trial data actually shows, why retatrutide hits the gut harder than a single-receptor GLP-1, how long the diarrhea typically lasts, and the management steps that work.

What the Phase 2 trial actually reported

The Phase 2 retatrutide obesity trial enrolled 338 adults with obesity and randomized them to placebo or one of four maximum maintenance doses: 1 mg, 4 mg, 8 mg, or 12 mg weekly, with slow or fast escalation arms ^[1]. Gastrointestinal side effects dominated the safety profile. Nausea, vomiting, diarrhea, and constipation all ran higher on retatrutide than on placebo, and all four showed a dose-response pattern.

For diarrhea specifically, the trial reported rates that climbed with dose. At the 12 mg maintenance dose, about 21% of participants experienced diarrhea over the 48 week trial. Placebo sat near 9%. The mid doses landed between those two endpoints. Most episodes were graded mild to moderate. Severe diarrhea was rare and discontinuation specifically because of diarrhea was even rarer; the overall GI-related discontinuation rate across all retatrutide doses was in the single digits.

The Phase 2 type 2 diabetes trial published in The Lancet later that year showed a similar pattern in a different population ^[2]. Diarrhea was again one of the most common adverse events, again dose dependent, again concentrated during dose escalation rather than once a stable dose was reached. The retatrutide MASLD trial in Nature Medicine in 2024 replicated the same signal at the same dose tiers ^[3].

So this is not a quirk of a single trial. Retatrutide and diarrhea are linked across three published Phase 2 datasets in three different patient populations. The link is real, the magnitude is roughly one in five at maximum dose, and the timing is concentrated around dose changes.

Why retatrutide causes diarrhea more than older GLP-1s

Semaglutide and tirzepatide also cause diarrhea. The class effect is well established. What makes retatrutide notable is that it adds a third receptor target on top of the two that tirzepatide already hits. Retatrutide is a triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. Each receptor pulls on a different gut mechanism.

GLP-1 receptor activation slows gastric emptying. Food sits longer in the stomach, then exits in larger, less processed boluses into the small intestine. The intestinal lining responds with increased fluid secretion, which speeds colonic transit and produces loose stools. This is the same mechanism that drives diarrhea on semaglutide, liraglutide, and tirzepatide.

GIP receptor activation contributes a smaller GI signal. The dominant GIP effects are on insulin secretion and lipid handling. GIP-only agonism does not produce the same diarrhea profile as GLP-1 agonism, which is part of why tirzepatide's GI side effect rate is not double that of semaglutide despite hitting both receptors.

Glucagon receptor activation is where retatrutide differentiates from its predecessors. Glucagon receptors are expressed on the liver, on adipose tissue, and on the gut. Activating them increases hepatic glucose output, raises energy expenditure, and changes bile acid handling. Altered bile acid composition reaching the colon is a known driver of bile acid diarrhea, and clinicians who treat patients on retatrutide have flagged this mechanism as a probable contributor to the loose stool pattern that some users report well after gastric emptying should have adapted.

The practical takeaway: if you have used semaglutide or tirzepatide before and tolerated them well, your odds with retatrutide are still good, but the glucagon component adds a GI mechanism those drugs do not have. Do not assume your old tolerance carries over one to one.

When the diarrhea hits and how long it lasts

The trial timing is consistent. Diarrhea episodes cluster in the days immediately following a dose escalation step. The Phase 2 protocol stepped doses up every four weeks, and adverse event logs showed a fresh spike of GI complaints in the first one to two weeks after each step. Once participants held a dose for a full month, the rate dropped back toward baseline.

For an individual user, the typical pattern looks like this. You take the new dose. Within one to five days you notice loose stools, sometimes urgency, sometimes two or three trips to the bathroom in a morning where you would normally have one. The intensity peaks around the middle of the first week. By the end of week two on the new dose, most people are back to a stool pattern that is closer to their baseline. By week four, they are stable. Then the next dose increase happens and the cycle repeats, usually milder than the previous step because the gut has been progressively adapting.

If the diarrhea persists for more than two weeks at a stable dose, that is no longer a typical titration response. The most common reasons are: a dose increase that was too aggressive, dietary changes you made for weight loss that are themselves driving the loose stools, or an underlying GI condition that the drug has unmasked. At that point the right move is to pause the next planned escalation, talk to your prescriber, and rule out other causes before assuming the drug is solely responsible.

How dose-escalation speed changes the diarrhea picture

This is the single variable most people underestimate. The Phase 2 trial tested both gradual and fast escalation to the same target dose. Fast escalation to 8 mg produced markedly more GI adverse events than gradual escalation to 8 mg, even though both groups ended at the same weekly dose. Slow titration buys gut adaptation time. Fast titration does not.

The Phase 3 TRIUMPH program adopted a slower escalation schedule for that reason. If your protocol jumps from 2 mg to 4 mg in two weeks, then to 8 mg two weeks after that, expect more diarrhea than if you held each step for four weeks. The destination is the same. The journey is what determines whether you spend a month in the bathroom.

How to prevent and manage retatrutide diarrhea

Two layers here. Prevention, which is everything you do before symptoms hit. Management, which is what you do once they show up.

Prevention

Stick to the slow titration schedule. If your prescriber offers a four-week hold at each dose, take it. Skipping ahead because the lower dose feels easy is the single most common reason people end up with severe GI symptoms two weeks later.

Eat smaller, lower-fat meals on injection day. GLP-1 induced gastric emptying delay is at its peak in the 24 to 48 hours after a dose. Heavy or greasy meals during that window are the most reliable trigger for both nausea and loose stools. Aim for 300 to 400 calorie meals every few hours instead of two large meals.

Hydrate before the dose, not just after. A dehydrated colon is more reactive. Two extra glasses of water in the 24 hours leading into your injection give the gut a buffer for whatever fluid shifts come next.

Pre-position electrolytes. Diarrhea drains sodium, potassium, and magnesium. Keep an oral rehydration packet, a low-sugar electrolyte drink, or just salt and broth on hand before you need it. People who have to drive to a pharmacy at 6 a.m. on day two of a dose increase invariably regret not stocking up earlier.

Management once it starts

Stay ahead of dehydration. Sip fluids continuously rather than chugging large volumes at once. Aim for clear urine. If you cannot keep fluids down because of concurrent nausea or vomiting, that is the threshold to call your prescriber and likely pause the next dose.

Use the BRAT framework loosely. Bananas, rice, applesauce, toast. The point is low-fiber, low-fat, low-residue food for one to three days. You are not trying to eat for nutrition during an acute episode; you are trying to give the colon less material to work with while it settles.

Cut high-FODMAP foods temporarily. Beans, broccoli, cauliflower, onions, garlic, large amounts of dairy. Bacterial fermentation of these in a slowed-transit gut amplifies both gas and loose stools. Reintroduce them once the dose has been stable for two to three weeks.

Loperamide is appropriate for symptomatic relief. Over-the-counter loperamide (Imodium) at standard doses is reasonable for an acute episode of GLP-1 induced diarrhea in an adult who is not pregnant and has no contraindications. Stick to the labeled dose. Do not stack it day after day for weeks without checking in with your prescriber, and never exceed the maximum daily dose; the FDA has flagged cardiac arrhythmia risk with high-dose loperamide misuse ^[4].

Probiotics may help and are unlikely to hurt. The evidence for routine probiotic use in GLP-1 induced diarrhea is mixed. A standard Lactobacillus or Saccharomyces boulardii product for one to two weeks during a flare is a reasonable trial. If it works for you, keep it. If it does nothing after two weeks, stop.

Slow or pause the next escalation step. This is the lever your prescriber controls, and it is the most effective one. If a 4 mg to 8 mg jump produces a week of diarrhea, the right response is to hold at 6 mg (if your formulation allows) or stay at 4 mg for an extra month before trying again. People who insist on hitting their target dose on schedule are the ones who end up quitting the drug entirely.

When diarrhea is a reason to stop or call your doctor

Most retatrutide diarrhea is mild, self-limiting, and resolves with the steps above. Some patterns are different and warrant medical attention.

Call your prescriber within 24 to 48 hours if:

• The diarrhea lasts more than 72 hours at a stable dose despite the management steps above.
• You cannot keep oral fluids down because of concurrent nausea or vomiting.
• You see blood in the stool, or stool that looks black and tarry.
• You have signs of dehydration: dark concentrated urine, no urination for eight hours, dizziness on standing, racing heart rate, dry mouth that does not improve with sipping water.
• You have severe abdominal pain, especially upper-abdominal pain that radiates to the back. This is the textbook presentation of pancreatitis, which is a known rare risk with GLP-1 class drugs and which Phase 2 retatrutide data tracked at low but non-zero rates.

Seek emergency care immediately for high fever with diarrhea, signs of shock (cold clammy skin, confusion, severe weakness), or persistent severe abdominal pain.

Does retatrutide make you poop more in general?

This is a slightly different question. Diarrhea (loose, urgent, watery stools) is one pattern. Increased stool frequency at a normal consistency is another, and so is the opposite, constipation. Retatrutide affects gut motility in both directions depending on the user. The Phase 2 data showed both diarrhea (21% at 12 mg) and constipation (around 11% at 12 mg) running well above placebo. A given user might experience one or the other or alternation between the two during titration.

If your pattern is increased frequency without urgency or true diarrhea, the management is different: keep fiber and water steady, avoid stacking laxatives or anti-diarrheals on top, and give the gut four to six weeks at a stable dose to settle into a new normal rhythm. Real diarrhea, with watery stool and urgency, is treated as described above.

Common questions about retatrutide and the gut

How common is diarrhea on retatrutide?

About 21% of participants on the 12 mg dose in the Phase 2 obesity trial, compared with 9% on placebo. Lower doses sit closer to the placebo rate. The pattern is dose dependent.

How long does retatrutide diarrhea last?

Most episodes peak within the first one to two weeks after a dose increase and resolve within two to four weeks at a stable dose. Diarrhea that lasts longer than two weeks at a stable dose is no longer typical and warrants a call to your prescriber.

Does retatrutide make you nauseous?

Yes. Nausea is the single most common adverse event, reaching roughly 27% in Phase 2 at the 12 mg dose. Like diarrhea, it is dose dependent and concentrated during escalation. Both side effects often appear together in the first days after a dose increase.

Does retatrutide make you poop more?

It changes bowel habits in both directions. Some users report diarrhea, others report constipation, some alternate between the two during titration. Increased stool frequency without true diarrhea typically settles within four to six weeks at a stable dose.

Does retatrutide cause acid reflux or heartburn?

Retatrutide slows gastric emptying, which can worsen reflux symptoms in people prone to GERD. Trial data captured dyspepsia and upper abdominal discomfort at low single-digit rates. Smaller meals, avoiding late-night eating, and standard OTC antacids help most cases.

Does retatrutide cause bloating?

Yes, bloating is reported. Slowed gastric emptying plus altered bacterial fermentation in the small intestine produces gas and abdominal distension, especially with high-fiber or high-FODMAP meals during the first weeks of a new dose.

Are sulfur burps from retatrutide normal?

Sulfur or rotten-egg burps are reported by a meaningful minority of users on GLP-1 class drugs and have been described on retatrutide as well. The mechanism is bacterial fermentation of sulfur-containing foods (eggs, meat, cruciferous vegetables) in a stomach that is emptying slowly. Cutting those foods for a few days usually resolves it.

Does retatrutide cause vomiting?

Yes, about 11% of Phase 2 participants reported vomiting at the 12 mg dose. The pattern matches nausea: episodic, concentrated in the first hours to days after a dose, dose dependent, and reduced by slow titration and smaller meals.

Can I take loperamide (Imodium) for retatrutide diarrhea?

For an acute episode, standard OTC loperamide doses are generally appropriate in adults without contraindications. Do not exceed the labeled maximum daily dose and do not use it continuously for weeks without checking in with your prescriber. High-dose loperamide misuse has been flagged by the FDA for cardiac arrhythmia risk.

When should I stop retatrutide because of diarrhea?

You do not need to stop for typical mild to moderate diarrhea that responds to hydration and dose-pacing. Reasons to pause or stop and call your prescriber include diarrhea lasting more than 72 hours despite management, blood in the stool, inability to keep fluids down, signs of dehydration, or severe abdominal pain (especially upper-abdominal pain radiating to the back, which can signal pancreatitis).

The bottom line

Retatrutide causes diarrhea in about one in five users at the maximum studied dose, in a pattern that is dose dependent, concentrated around dose increases, and usually self-limiting within two to four weeks at a stable dose ^[1]. The triple-agonist mechanism (GLP-1, GIP, glucagon) gives it a slightly different GI profile than single or dual agonists, with the glucagon component contributing an extra signal through bile acid handling that semaglutide and tirzepatide do not have.

The single most effective preventive step is slow titration. The single most effective acute step is hydration with electrolytes plus a short course of loperamide if needed. Persistent severe diarrhea, blood in the stool, or signs of dehydration are reasons to pause the drug and call your prescriber rather than push through.